The NPs-based immunotherapy showed a significant reduction in the effective doses of volasertib and the PD-L1 antibody by five-fold in a metastatic lung in vivo tumor model by actively mediating CD8+ T cells, allowing the immune cells to induce their cytotoxic activity on the cancer cells. Here, CD8A is linked to neoplasm.